WASHINGTON — Today, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) of the University College London released the results of its study to determine if the risk of ovarian cancer algorithm (ROCA), when used yearly in conjunction with the CA-125 blood test, helps screen for ovarian cancer and lower mortality rates among post-menopausal women. The study found that combining ROCA with the CA-125 blood test lowers the mortality rate by 20 percent on average for post-menopausal women within the parameters of the study, which was not found to be statistically significant. More specifically, the test reduces mortality at a rate of 8 percent during years 0-7 of having ROCA run annually and 28 percent during years 7-14.
In response to the UKCTOCS study results, Ovarian Cancer National Alliance (OCNA) CEO Calaneet Balas issued the following statement:
“These initial results are promising for the ovarian cancer community, but there is much more data analysis needed in the coming months to determine the true impact on the future of early detection testing for ovarian cancer. We are looking forward to discussions with the community in the coming months to understand how ROCA may fit into the prevention of ovarian cancer.
“Ovarian cancer is a devastating, deadly disease that takes the lives of over 14,000 women each year in the United States. There is no early detection test and the symptoms are often confused with other diseases, leaving 85 percent of women diagnosed in a late stage. Early detection is the key to surviving ovarian cancer and today’s findings show promise for post-menopausal women.
“The Ovarian Cancer National Alliance will continue its work with lawmakers, the ovarian cancer community and those providing care to ensure that women have access to the health care they need.”
To watch the full announcement from UK Collaborative Trial of Ovarian Cancer Screening of the University College London, click here.
To read the study published in The Lancet, click here.